Epithelial-mesenchymal transition
Curr Issues Pharm Med Sci., Vol. 36, No. 1, 18-20
Joanna Kubik*
, Kamil Pawlak
Independent Medical Biology Unit, Medical University of Lublin, Poland
10.2478/cipms-2022-0005
© 2023 Author(s). This is an open access article distributed under the Creative Commons Attribution-NonComercial-No Derivs licence (http://creativecommons.org/licenses/by-nc-nd/3.0/)
Abstract
The process of epithelial-mesenchymal transition (EMT) occurs in both physiological and pathological states, and there are increasing links between EMT and tumor progression. During this process, dynamic changes in cell organization and function occur that promote migration and invasion. A better understanding of the mechanism of plastic EMT may help develop novel targeted therapies that can help treat cancers of varying degrees of malignancy. Our review helps to systematize knowledge of the molecular and biochemical mechanisms involved in the EMT process in both tumor and physiological backgrounds.
Full Text
Keywords
epithelial-mesenchymal transition, cancer metastasis, circulating tumor cells, epithelial markers.
References
- Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119:1420-8.
- Kim D, Xing T, Yang Z, Dudek R, Lu Q, Chen Y-H. Epithelial mesenchymal transition in embryonic development, tissue repair and cancer: A comprehensive overview. JCM. 2017;7:1.
- Thiery JP, Acloque H, Huang RYJ, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139: 871-90.
- Marconi GD, Fonticoli L, Rajan TS, Pierdomenico SD, Trubiani O, Pizzicannella J, et al. Epithelial-mesenchymal transition (EMT): The type-2 EMT in wound healing, tissue regeneration and organ fibrosis. Cells. 2021;10:1587.
- López‐Novoa JM, Nieto MA. Inflammation and EMT: An alliance towards organ fibrosis and cancer progression. EMBO Mol Med. 2009;1:303-14.
- Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009;119:1429-37.
- Yang J, Du X, Wang G, Sun Y, Chen K, Zhu X, et al. W. Mesenchymal to epithelial transition in sarcomas. EJC. 2014;50:593-601.
- Dillekås H, Rogers MS, Straume O. Are 90% of deaths from cancer caused by cetastases? Cancer Med. 2019;8:5574-6.
- Jie X-X, Zhang X-Y, Xu C-J. Epithelial-to-mesenchymal transition, circulating tumor cells and cancer metastasis: Mechanisms and clinical applications. Oncotarget. 2017;8:81558-71.
- Genna A, Vanwynsberghe AM, Villard AV, Pottier C, Ancel J, Polette M, et al. EMT-associated heterogeneity in circulating tumor cells: Sticky friends on the road to metastasis. Cancers (Basel.) 2020;12:1632.
- Zheng X, Dai F, Feng L, Zou H, Feng L, Xu M. Communication between epithelial–mesenchymal plasticity and cancer stem cells: New insights into cancer progression. Front Oncol. 2021;11:617597.
- Petrova YI, Schecterson L, Gumbiner BM. Roles for e-cadherin cell surface regulation in cancer. Mol Biol Cell. 2016;27:3233-44.
- Couchman JR, Chen L, Woods A. Syndecans and cell adhesion. Int Rev Cytol. 2001;207:113-50.
- Li B, Shen W, Peng H, Li Y, Chen F, Zheng L, et al. Fibronectin 1 promotes melanoma proliferation and metastasis by inhibiting apoptosis and regulating EMT. OTT. 2019;12:3207-21.
- Wang M, Ren D, Guo W, Huang S, Wang Z, Li Q, et al. N-cadherin promotes epithelial-mesenchymal transition and cancer stem cell-like traits via ErbB signaling in prostate cancer cells. IJC. 2016;48:595-606.
